|
Sign In to gain access to subscriptions and/or personal tools.
|
Clinical Pediatrics, Vol. 39, No. 1,
15-25 (2000)
DOI: 10.1177/000992280003900102
A Pilot Study of Methyiphenidate, Clonidine, or the Combination in ADHD Comorbid with Aggressive Oppositional Defiant or Conduct Disorder
Daniel F. Connor, MD
Division of Child and Adolescent Psychiatry and Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA; Department of Psychiatry, 7th floor, University of Massachusetts Medical School, 55 Lake Ave., North, Worcester, MA 01655
Russell A. Barkley, PhD
Heather T. Davis, RN, MS, CS
Division of Child and Adolescent Psychiatry and Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA
A pilot comparison of the safety and efficacy of methylphenidate (MPH) combined with clonidine, clonidine monotherapy, or MPH monotherapy in 6to 16-year-old children diagnosed with attention deficit hyperactivity disorder (ADHD) and comorbid aggressive oppositional defiant disorder or conduct disorder was completed. Study design was a 3-month, randomized, blinded, group comparison with eight subjects per group. No placebo comparison was used. All three treatment groups showed significant improvements in attention deficits, impulsivity, oppositional, and conduct disordered symptoms as assessed by parent and teacher rating scales and laboratory measures. Significant differences among treatment groups were found only on a few measures. Only the clonidine monotherapy group showed significantly decreased fine motor speed. These results suggest the safety and efficacy of clonidine alone or in combination with MPH for the treatment of ADHD and aggressive oppositional and conduct disorders.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. Biederman, R. D. Melmed, A. Patel, K. McBurnett, J. Konow, A. Lyne, N. Scherer, and for the SPD503 Study Group
A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Pediatrics,
January 1, 2008;
121(1):
e73 - e84.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. G. Wood, J. L. Crager, C. M. Delap, and K. D. Heiskell
Literature Review: Beyond Methylphenidate: Nonstimulant Medications for Youth With ADHD
J Atten Disord,
November 1, 2007;
11(3):
341 - 350.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C R Steer
Managing attention deficit/hyperactivity disorder: unmet needs and future directions
Arch. Dis. Child.,
February 1, 2005;
90(suppl_1):
i19 - i25.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Burke, R. Loeber, and B. Birmaher
Oppositional Defiant Disorder and Conduct Disorder: A Review Of The Past 10 Years, Part II
Focus,
October 1, 2004;
2(4):
558 - 576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Bennett, M. Pitale, V. Vora, and A. A. Rheingold
Reactive vs. proactive antisocial behavior: Differential correlates of child ADHD symptoms?
J Atten Disord,
May 1, 2004;
7(4):
197 - 204.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Bhatara, M. Feil, K. Hoagwood, B. Vitiello, and B. Zima
National trends in concomitant psychotropic medication with stimulants in pediatric visits: Practice versus knowledge
J Atten Disord,
May 1, 2004;
7(4):
217 - 226.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Safer, J. M. Zito, and S. dosReis
Concomitant Psychotropic Medication for Youths
Am J Psychiatry,
March 1, 2003;
160(3):
438 - 449.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. F. Connor, R. T. Boone, R. J. Steingard, I. D. Lopez, and R. H. Melloni JR
Psychopharmacology and Aggression: II. A Meta-Analysis of Nonstimulant Medication Effects on Overt Aggression-Related Behaviors in Youth with SED
Journal of Emotional and Behavioral Disorders,
January 1, 2003;
11(3):
157 - 168.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Scahill, P. B. Chappell, Y. S. Kim, R. T. Schultz, L. Katsovich, E. Shepherd, A. F.T. Arnsten, D. J. Cohen, and J. F. Leckman
A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder
Am J Psychiatry,
July 1, 2001;
158(7):
1067 - 1074.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. J. Millan, F. Lejeune, A. Gobert, M. Brocco, A. Auclair, C. Bosc, J.-M. Rivet, J.-M. Lacoste, A. Cordi, and A. Dekeyne
S18616, a Highly Potent Spiroimidazoline Agonist at alpha 2-Adrenoceptors: II. Influence on Monoaminergic Transmission, Motor Function, and Anxiety in Comparison with Dexmedetomidine and Clonidine
J. Pharmacol. Exp. Ther.,
December 1, 2000;
295(3):
1206 - 1222.
[Abstract]
[Full Text]
|
 |
|
|